Please assess the completion status of the following clinical trial:

Trial Title: PORtopulmonary Hypertension Treatment wIth maCitentan - a randOmized Clinical Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Main Inclusion Criteria:~* Male or female of at least 18 years of age~* Confirmed diagnosis of portopulmonary hypertension~Main Exclusion Criteria:~* Severe hepatic impairment~* Severe obstructive or restrictive lung disease~* Pulmonary veno-occlusive disease~* Systolic blood pressure (SBP) \< 90 mmHg at Screening~* ALT/AST \>= 3 x ULN~* Bilirubin \>= 3 mg/dL at Screening~* Any known factor or disease that might interfere with treatment compliance, study conduct, or interpretation of results

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Investigational treatment (Type: EXPERIMENTAL): Macitentan film-coated tablet 10 mg once daily.
- Placebo (Type: PLACEBO_COMPARATOR): Matching placebo tablet once daily.

Based on this trial design, predict the completion outcome and termination type (if applicable).